Hi, I'm Dan Pramak and welcome to Axios Recap.

Today's Thursday, January 14th.

Weekly jobless claims are up, new job postings are down year over year,

and we're focused on what comes next in the vaccine race.

As all of you certainly know by now, America has become a two-vaccine nation, with

healthcare workers, first responders, and seniors getting injected with products from

either Pfizer or Moderna.

And as you also probably know, those vaccines each require a double dose, are difficult to store, and there's

simply not enough of either yet to go around, even if the rollout was being handled more

efficiently.

What's gotten less attention, though, is that plenty of other companies are continuing to

work on new coronavirus vaccines.

For example, Johnson Johnson, which last night released promising interim results and said

its full phase three data is expected to come later in the month.

Why it matters is that more developed and approved vaccines could mean an acceleration

of vaccinations, pushing us toward that holy grail of herd immunity, particularly if there

becomes some sort of future manufacturing problem

or other problem with what's currently in the market.

So we wanted to speak again with medicinal chemist and biotech blogger Derek Lowe to better understand the pipeline.

So Derek, let's start with this new interim data release from Johnson Johnson, which

says that by the end of the month it should be releasing its phase three trial data.

Should we take this to mean that we could see J&J vaccines in people's arms in a little over

...